4.66
-0.03(-0.64%)
Currency In USD
| Previous Close | 4.69 |
| Open | 4.73 |
| Day High | 5.14 |
| Day Low | 4.49 |
| 52-Week High | 5.94 |
| 52-Week Low | 2.03 |
| Volume | 796,764 |
| Average Volume | 134,692 |
| Market Cap | 244.03M |
| PE | -4.85 |
| EPS | -0.96 |
| Moving Average 50 Days | 3.74 |
| Moving Average 200 Days | 3.32 |
| Change | -0.03 |
If you invested $1000 in Sight Sciences, Inc. (SGHT) since IPO date, it would be worth $139.1 as of October 20, 2025 at a share price of $4.66. Whereas If you bought $1000 worth of Sight Sciences, Inc. (SGHT) shares 3 years ago, it would be worth $664.76 as of October 20, 2025 at a share price of $4.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
GlobeNewswire Inc.
Oct 17, 2025 11:00 AM GMT
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to t
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucomaMENLO PAR
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
GlobeNewswire Inc.
Sep 09, 2025 11:05 AM GMT
UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessaryMENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nas